Leap Therapeutics Inc. (LPTX)
| Bid | 0.3 |
| Market Cap | 12.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.81 |
| PE Ratio (ttm) | -0.17 |
| Forward PE | -0.51 |
| Analyst | Hold |
| Ask | 0.34 |
| Volume | 531,804 |
| Avg. Volume (20D) | 2,646,746 |
| Open | 0.31 |
| Previous Close | 0.34 |
| Day's Range | 0.30 - 0.33 |
| 52-Week Range | 0.28 - 4.79 |
| Beta | 0.21 |
About LPTX
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and com...
Analyst Forecast
According to 2 analyst ratings, the average rating for LPTX stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 2479.81% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon CancerLeap Therapeutics focuses on developing DKN-01, a promising monoclonal antibody for solid tumors, with encouraging early trial data in GI cancers. LPTX has a short operational runway with less than a ...